Results with Lifescozul™Breast Cancer
Introduction to the case
Breast cancer is the most common cancer among women and is responsible for the highest number of deaths from tumors. Among its most aggressive types is Triple Negative, which grows and spreads faster, has limited treatment options and a worse prognosis for the patient.
Cecilia was diagnosed with Colon Cancer 4 years ago, which thanks to chemotherapy and surgery she managed to overcome.
Unfortunately in January 2020 Cecilia was diagnosed with another type of cancer, Triple Negative Infiltrating Ductal Carcinoma.
Cecilia had noticed that in her left breast there was a mass, and at the time of an ultrasound it was revealed that the mass measured 7 centimeters, a very large tumor that represented a great risk.
The size of the nodule, being 68 years old and having a diagnosis of Triple Negative cancer left Cecilia with very little chance of survival, something that her son Juan, who is a doctor, was very clear about.
Wanting to save his mother's life, Juan decided to look for a treatment to complement the chemotherapy sessions and thus attack the disease with more strength.
At that moment, a colleague told him about LifEscozul (the most effective formulation made with blue scorpion venom), and after thoroughly investigating the properties of blue scorpion venom and seeing its excellent results in other patients, he decided to contact us.
Let's see Cecilia's results below.
Cecilia Jacinta Jacinta Ochoa De Corredor, 69 years old at the beginning of treatment with LifEscozul.
Specialist assigned to Grupo LifEscozul™
Dr. Aaron Sarmiento
Suspicious lesion of malignancy in left breast, BIRADS IVC.
Cecilia is a patient with a history of Colon Cancer, which she managed to overcome thanks to surgery and chemotherapy.
Four years later, Cecilia felt a large mass in her left breast, an ultrasound was performed and it was revealed that the tumor measured 7 centimeters. In January 2020 Cecilia was diagnosed with a poorly differentiated Infiltrating Ductal Carcinoma (Grade III) triple negative in the left breast.
Her prognosis was worse due to the size of the tumor, her age and the fact that her cancer was Triple Negative.
Her son Juan heard about the LifEscozul Group and its results in cancer treatment, so he contacted us and sent us all the medical documentation of Cecilia, who was admitted to our Protocol and in February 2020 began treatment with LifEscozul (escozul, blue scorpion venom, escoazul) under the supervision of Dr. Aaron Sarmiento.
At this time Cecilia was undergoing chemotherapy.
Evolution with LifEscozul™ and actual results
3 WEEKS TAKING LIFESCOZUL
Since the beginning of the treatment, Juan has been in frequent contact with our Medical Team, keeping us updated on his mother's evolution, especially due to the severity of her disease.
When Cecilia underwent an ultrasound scan with tumor marking 3 weeks after starting treatment with LifEscozul (the most effective formulation made with blue scorpion venom), there was a progressive decrease of the tumor on palpation.
Twenty days after starting treatment with LifEscozul, Cecilia began the cycle of chemotherapy, reporting good tolerance: she felt no side effects at any time, did not lose weight or appetite and her mood was intact.
Cecilia's quality of life was not affected, which allowed her to continue to attend work without fail and carry out her daily activities without discomfort.
In early July 2020, 5 months into the joint use of LifEscozul (escozul, blue scorpion venom, escoazul) and chemotherapy, we were informed that Cecilia continued to be in good physical condition and that there was tumor shrinkage.
When a second tumor marking was performed, the results continue to indicate that the tumor continues to progressively decrease in size.
It is important to highlight that during all this time Cecilia has not interrupted her chemotherapy sessions nor the treatment with LifEscozul (the most effective formulation elaborated with the blue scorpion venom).
In September 2020, 7 months after starting our treatment, the mammography report indicated that there was no presence of tumor residue, although the ultrasound indicated the presence of a small lesion reduced to 4 millimeters in size.
This result represented a great advance in her recovery, considering that at the beginning her prognosis was not encouraging.
The combination of chemotherapy sessions with the LifEscozul treatment (escozul, blue scorpion venom, escoazul) managed to effectively fight Cecilia's cancer.
She is currently under constant surveillance by our LifEscozulMedical Team.
In January 2020 Cecilia was diagnosed with a poorly differentiated (Grade III) Triple Negative Infiltrating Ductal Infiltrating Carcinoma in the left breast. This diagnosis left her with very few treatment options, so her son Juan looked for other alternatives that could help his mother overcome her disease.
In February 2020 Juan contacted us, and in that same month Cecilia started treatment with LifEscozul (the most effective formulation made with blue scorpion venom).
Cecilia's results after a few months of treatment with LifEscozul in conjunction with chemotherapy sessions were immediate, showing a rapid reduction in the size of the tumor, reaching the point of measuring only 4 millimeters.
Another result to highlight is the fact that Cecilia did not present any side effects from the chemotherapies.
Her quality of life was not affected, Cecilia attends work every day and continues to be a very energetic woman.
Her case will continue to be observed by our Medical Team for 5 more years.
We are the LifEscozul Group and Results Define Us.
Juan José Rodríguez
Mr. Juan Jose was diagnosed with prostate cancer discovered after 3 biopsies, which were performed due to successive increases in PSA. "The diagnosis of prostate cancer is usually based on the results of a clinical examination of the prostate and a blood test in which the levels of a protein called prostate-specific antigen (PSA) are checked, as well as the results of a biopsy."The diagnosis of prostate cancer is usually based on the results of a clinical examination of the prostate and a blood test in which the levels of a protein called prostate-specific antigen (PSA) are checked, as well as the results of a biopsy. View more